Both preclinical and clinical evidence suggests that the endogenous opioid system is involved in responses to stress. For example, in animal models opioid agonists reduce isolation distress whereas opioid antagonists increase isolation distress. We recently reported that the mixed mu agonist and kappa antagonist buprenorphine dampened responses to acute psychosocial stress in humans. Now we extend this to study the effects of a pure mu-opioid agonist, hydromorphone, and a non-opioid analgesic, acetaminophen, on response to social stress. We compared the effect of hydromorphone (2 and 4 mg), acetaminophen (1000 mg) to a placebo using a between subject design. Healthy adult volunteers were randomly assigned to receive placebo (N = 13), 2 mg hydromorphone (N = 12), 4 mg hydromorphone (N = 12), or 1000 mg acetaminophen (paracetamol; N = 13) under double-blind conditions before undergoing a stress task or a control task on two separate sessions. The stress task, consisting of a standardized speaking task and the non-stressful control task were presented in counterbalanced order. Dependent measures included mood ratings, subjective appraisal of the stress (or no-stress) task, salivary cortisol, pupil diameter, heart rate, and blood pressure. The stress task produced its expected increase in heart rate, blood pressure, salivary cortisol, pupil diameter, and subjective ratings of anxiety and negative mood. Hydromorphone dose-dependently dampened cortisol responses to stress, and decreased ratings of how "challenging" participants found the task. Acetaminophen did not affect physiological responses, but, like hydromorphone, decreased ratings of how "challenging" the task was. The hydromorphone results support the idea that the mu-opioid system is involved in physiological responses to acute stress in humans, in line with results from preclinical studies. The non-opioid analgesic acetaminophen did not dampen physiological responses, but did reduce some components of psychological stress. It remains to be determined how both opioid and nonopioid systems mediate the complex physiological and psychological responses to social stress.
Introduction
Recent evidence from imaging and pharmacological studies suggests that the endogenous opioid system plays an important role in the regulation of negative affect in humans and other species (for a review see Lutz and Kieffer, 2013) . That is, beyond its role in alleviating responses to physical pain, the opioid system may also be involved in responses to "psychological" pain, or negative affect not associated with physical pain. This idea is supported by imaging studies indicating that the muopioid system is involved in responding to negative affective experiences (Hsu et al., 2013; Hsu et al., 2015; Zubieta et al., 2003) and by preclinical studies showing that low doses of mu-opioid agonists dampen responses to social isolation distress Panksepp et al., 1978; Stein et al., 2007) , predator odors (Wilson and Junor, 2008) , fear acquisition (Good and Westbrook, 1995) and anxiety-like behavior in the elevated plus maze (Kahveci et al., 2006) . These findings raise the possibility that opioid drugs might reduce psychological or physiological responses to stress in humans. A first step to examine this possibility is to test responses to acute psychosocial stress in healthy adults. We have previously assessed the effects of the partial mu-opioid agonist and kappa-antagonist buprenorphine on responses to stress and other emotional stimuli in healthy adult volunteers, showing that the drug reduces subjective and physiological responses to acute psychosocial stress (Bershad et al. 2015; . Buprenorphine has a complex mechanism of action, and an important follow-up to these studies is addressing whether the effects we observed in our previous study are due to mu-or kappa-opioid mechanisms. While a pure kappa antagonist is not yet available for use in humans, we attempted to address this question by assessing the effects of a pure mu-agonist, hydromorphone, on responses to psychosocial stress.
The opioid system has been implicated in negative affect induced by acute stress. Mu-opioid receptors are highly expressed in regions of the brain involved in the stress response including the bed nucleus of the stria terminalis, central amygdala, and paraventricular nucleus of the hypothalamus (Mansour et al., 1995; Peckys and Landwehrmeyer, 1999; Simonin et al., 1995) . In humans, polymorphisms in the muopioid receptor gene (OPRM1) predict cortisol responses to social stress (Chong et al., 2005) . The opiate heroin, acting indirectly as a muagonist, reduces amygdala response to fearful faces (Schmidt et al., 2013) and lowers cortisol levels in heroin-dependent individuals (Rasheed and Tareen, 1994) , suggesting that it decreases reactivity to stress. Most recently, we (Bershad et al., 2015) reported that very low doses of buprenorphine reduced cortisol responses to acute social stress (i.e., public speaking) in healthy volunteers. Although the stress-dampening effects with buprenorphine may have been related to either its mu-agonist effects or its kappa-antagonist effects, recent findings suggest that the anti-depressant-like or anti-stress effects of buprenorphine are related to its kappa-antagonist effects (Carlezon and Krystal, 2016; Carr et al., 2010; Falcon et al., 2016; Falcon et al., 2014; Knoll et al., 2011; Land et al., 2008; McLaughlin et al., 2005; McLaughlin et al., 2003) . Therefore, in the present study we examined the effect of hydromorphone, a mu-agonist without kappa actions, on responses to social stress.
A secondary goal in this study was to determine whether another analgesic medication that does not directly act on opioid receptors affects response to psychosocial stress. The neural networks involved in physical pain overlap with networks involved in emotional or social pain (for a review, see Eisenberger, 2015) , suggesting that other pain medications may also dampen affective responses to negative emotional stimuli. Acetaminophen (paracetamol) is considered a non-opioid analgesic (White, 2005) with primary action as a cyclooxygenase enzyme (COX) inhibitor, although it may have indirect opioidergic effects (Pini et al., 1997) . Interestingly, acetaminophen reduces responses to the uncomfortable affective experiences of social rejection, empathy for pain, and cognitive dissonance (DeWall et al., 2015; DeWall et al., 2010; Mischkowski et al., 2016; Randles et al., 2016) . Based on these observations we hypothesized that acetaminophen would also dampen responses to acute psychosocial stress.
Methods

Design
The study used a mixed between-subject (drug condition) and within-subject (stress, no stress) design. Healthy young adults were randomly assigned to one of four drug conditions: 2 mg hydromorphone (N = 12), 4 mg hydromorphone (N = 12), 1000 mg acetaminophen (N = 13), or placebo (N = 13). They participated in two 4-hour sessions separated by at least two days, one with a stress task and one with a control task. On both sessions, subjects ingested a capsule under double blind conditions, and 60 min later engaged in either the Trier Social Stress Test (TSST; Kirschbaum et al., 1993) or a non-stressful control task (NSCT), in counterbalanced order. The primary measures of responses to stress were physiological (i.e. heart rate, blood pressure, salivary cortisol and pupillometry) and subjective reports of mood and anxiety. The study was approved by the University of Chicago's Institutional Review Board and carried out in accordance with the Declaration of Helsinki.
Participants
Subjects (30 men, 20 women) were recruited through the use of online advertisements and flyers. Participants were 18-40 years old, and underwent medical and psychiatric screenings prior to enrollment.
They were excluded if they had a serious medical condition, abnormal electrocardiogram, Axis I psychiatric disorder (American Psychiatric Association, 1994) in the past year, or a history of psychosis. Subjects were also excluded if they had not completed high school, were not fluent in English, worked a night shift, used hormonal contraceptives, or were pregnant. Daily cigarette smokers were excluded. Further, because circulating hormones influence stress responses (Kirschbaum et al., 1999) , women were tested only during the follicular stage of their menstrual cycles, as assessed by self-report (i.e., within 10 days since menstruation).
Study drugs
Participants were randomly assigned to drug conditions, and received the same drug treatment during both sessions. They received 2 mg or 4 mg hydromorphone (Dilaudid, Rhodes Pharmaceuticals), 1000 mg acetaminophen (Extra Strength Tylenol, McNeil Consumer Healthcare), or placebo (dextrose, Fisher Scientific). Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion (Drover et al., 2002) , and the doses selected produce subjective effects (e.g. reports of "feel drug") comparable to the doses of buprenorphine we have used previously. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection (DeWall et al., 2010) , and it also peaks about 60 min after ingestion (Raffa et al., 2014) .
Procedure
At a 1-hour orientation session, the experimental procedure was described to subjects and they provided informed consent. They were told to abstain from alcohol and recreational drugs for 48 h before each session. Compliance was verified with urine (Rapid Drug Test Cup, CLIAwaived, San Diego, CA) and breath (Alco-Sensor III, Intoximeters, St. Louis, MO) tests. Subjects were told that they would receive a stimulant, sedative, cannabinoid, opioid, over-the-counter pain reliever, or placebo.
Subjects attended two sessions, during which they completed the TSST or NSCT. Sessions were conducted from noon to 4 pm separated by at least 48 h. Upon arrival, subjects were tested for the presence of drugs, alcohol and, in the case of women, pregnancy. Electrocardiogram (ECG) electrodes were then placed for cardiovascular monitoring. Baseline physiological and mood measures were taken, and subjects were given a standardized snack. They ingested the assigned capsule at 12:30 pm, and then relaxed for 40 min. Throughout the session, physiological and mood measures were obtained at regular intervals. Sixty minutes after taking the capsule, subjects were informed of their task for the day, and completed a questionnaire estimating how threatening and challenging they thought the task would be. For the TSST, subjects were given 10 min to prepare a 5-minute speech for a mock-job interview, followed by 5 min of serial subtraction in front of two examiners. Subjects were told these tasks would be videotaped and during the procedure they could see their own images projected on a video monitor. After the 10-minute preparation they completed the task. For the NSCT, were also given 10 min to prepare, but in this condition subjects spent 5 min describing a favorite movie, play or book to a research assistant, and then 5 min playing Solitaire on a computer. They were not videotaped during this task. Cardiovascular measures and pupil diameter were measured immediately before and 30, 60 and 90 min after the tasks, and subjects completed mood questionnaires at these same times. Additional salivary cortisol samples were collected 10, 20 and 60 min after the tasks.
Subjective measures
During each session, subjects completed questionnaires assessing their mood and subjective states at regular intervals. The Profile of Mood States (POMS; McNair et al., 1971 ) is a 72-item evaluation of current mood with subscales for Anxiety, Depression, Anger, Vigor, Fatigue, Confusion, Friendliness and Elation. The Drug Effects Questionnaire (DEQ; Fischman and Foltin, 1991) contains 5 visual analog scales that subjects use to rate their drug experience in terms of liking, disliking, feeling "high," and wanting more. Subjects also completed visual analogue scale ratings (VAS; 0-100 mm) of "stress," "tension," and "insecurity" immediately before being given instructions for the task and immediately after the task. Immediately before performing the verbal tasks, participants also completed the Primary Appraisal Secondary Appraisal rating scale (PASA; Gaab et al., 2005) to provide their anticipatory evaluations of the tasks prior to completing them. This measure is comprised of 16 items, rated 1-6 ("strongly agree" to "strongly disagree"). The questionnaire assesses the two dimensions of primary stress appraisal (8 questions each); threat and challenge, in addition to secondary measures of 'self-concept of own abilities' and "control expectancy". Immediately after the verbal tasks, participants completed a VAS rating of how satisfied they were with their performance.
Physiological measures
Heart rate was recorded using an ambulatory monitor (Mindware Technologies, Gahanna, OH), with a sampling rate of 500 Hz. Data were collected for 5 min at each time point, and analyzed in 60-second segments. Values were the mean over each 5-minute period. Blood pressure was assessed with portable monitors (Omron 790IT 10+ Series Upper Arm Blood Pressure Monitor, Omron, Lake Forest, IL). Measures of pupil diameter were obtained at a rate of 30 Hz (VIP™-200 Variable Pupillometer, NeurOptics, Irvine, CA) and averaged over a 2-s period at each time point. Salivary cortisol was collected with Salivette® cotton wads (Sarstedt, Newton, NC). Cortisol levels were determined by the University of Chicago's General Clinical Research Center (Salimetrics LLC, State College, PA, sensitivity = 0.003 μg/dL).
Task performance
An evaluator noted the number and length of pauses made by each subject during the interview portion of the TSST, and noted the number of times the subject made a mistake during the serial subtraction.
Statistical analysis
Analyses were conducted using SPSS version 16.0 for Windows. Missing cases (due to equipment malfunction or other data collection problems) were deleted list wise, which led to smaller sample sizes for some analyses. To verify that the four groups were matched, we compared demographic information and baseline measures between the groups using a one-way analysis of variance (ANOVA). Although we did not have power to compare men and women systematically, we included sex in the analyses as an exploratory measure and to minimize variability. Drug effects during the non-stressful control session provided a measure of the direct effect of the drugs, and these were analyzed using three-factor ANOVA for repeated measures, with time as the within-subjects factor and treatment group and sex as between-subjects factors. Results were analyzed using repeated measures ANOVAs, with task (TSST vs. NCST) and treatment group and sex as between-subject factors. Significant interactions were further investigated by one-way ANOVA and follow-up t-tests at each time point during stress. Repeatedmeasures ANOVAs were performed with Greenhouse-Geisser correction where violations of sphericity were observed. Differences were considered to be significant if p < 0.05. On certain, mainly physiological measures, data from 1 or 2 subjects were lost because of equipment problems, resulting in small variations in the final Ns.
Results
Demographics and baseline differences
Participants were mostly Caucasian and in their 20s (Table 1) . The groups did not differ on demographic characteristics, trait anxiety as measured by the State-Trait Anxiety Inventory (STAI-T; Spielberger et al., 1970) , drug use history, or on baseline measures of mood (POMS), heart rate, blood pressure, or salivary cortisol.
Drug effects
Hydromorphone (4 mg) produced modest increases on ratings of "feel drug" and "feel high." These effects began before the task, and continued to increase later in the session. During the non-stressful control session, hydromorphone (4 mg) tended to increase ratings of "feel drug" relative to placebo [ Fig. 1 ; Time * Drug F(15,210) = 1.7, . Hydromorphone did not significantly alter blood pressure, heart rate, or cortisol levels. Acetaminophen did not produce any significant subjective or physiological effects independently of the stress task. the TSST session, compared to the control session. On ratings of stress, there was an interaction between sex and task, such that women rated the TSST as more stressful than men: Task * Sex F(1,42) = 4.5, p < 0.05, ηρ 2 = 0.10; women vs. men: t(48) = 2.5, p < 0.05, d = 0.75). Beyond ratings of stress, there were no significant sex differences on subjective ratings.
Effects of hydromorphone and acetaminophen on TSST
Neither hydromorphone nor acetaminophen significantly affected ratings of stress or anxiety after the task. The drugs also did not alter performance during the task, as assessed by total number correct and number of restarts on the arithmetic task and number of pauses during the speech. While it is difficult to compare across studies, in our previous study, we showed that 0.4 mg buprenorphine dampened threat appraisal (mean change from placebo ± SEM = 1.0 ± 0.3), and in this study we observed no such effect (mean change from placebo ± SEM = 0.03 ± 0.2). Whereas subjects in the placebo condition rated the TSST task as being significantly more "challenging" than the control task, subjects in the three drug conditions did not rate the TSST as more "challenging" than the control task [Task * Drug F (3,42) = 3.1, p < 0.05, ηρ 2 = 0.21; TSST only significantly increased ratings of "challenging" in the placebo group]. Additionally, the TSST increased sympathetic activation as measured by pupil diameter [Task F(1,43) = 11.8, p < 0.01, ηρ 2 = 0.23] as compared to the control session. There were no interactions with sex on any of these measures. None of the physiological effects of the stress task were significantly correlated with subjective ratings of stress during the TSST session.
Effects of hydromorphone and acetaminophen
At 4 mg, hydromorphone blocked the increase in salivary cortisol seen after the TSST in the placebo group [ Fig. 4 ; Drug F(3, 42) = 3.2, p < 0.05, ηρ 2 = 0.22; 0 mg vs. 4 mg t(22) = 3.8, p < 0.01, d = 1.7 at 10-minute post TSST and t(22) = 3.2, p < 0.01, d = 1.4 at 20 min post TSST]. Hydromorphone did not significantly affect blood pressure or heart rate increases in response to the TSST. While it is difficult to compare across studies, our previous study, we showed that 0.2 mg and 0.4 mg buprenorphine blocked cortisol responses to stress (mean peak change from placebo ± SEM = −0.2 ± 0.03; −0.2 ± 0.04, respectively), slightly more strongly than 2 mg and 4 mg hydromorphone (mean peak change from placebo ± SEM = −0.07 ± 0.03; −0.1 ± 0.01, respectively). This was the case even though the drugs were matched with respect to the subjective ratings of "feel drug" they Fig. 1 . Time-course of subjective drug effects. Ratings of "feel drug" throughout the non-stressful control session. Shaded area indicates the time during which the task took place. Data points represent mean ± SEM. Neither drug significantly increased this measure. Fig. 2 . Drug effects on ratings of anxiety as measured by the POMS during a) the non-stressful control session (NCST) and b) the TSST session. Shaded area indicates the time during which the TSST took place. Data points represent mean ± SEM. Neither drug affected these measures.
produced (mean peak change from placebo ± SEM 0.2 mg buprenorphine: 12.1 ± 5.2; 0.4 mg buprenorphine: 24.3 ± 6.1; 2 mg hydromorphone: 11.4 ± 5.2; 4 mg hydromorphone: 18.5 ± 6.0).
Effects of acetaminophen
Acetaminophen did not significantly affect heart rate, blood pressure, or pupillary responses to stress. It did not significantly alter cortisol responses to stress.
Discussion
In this study, we assessed the effects of hydromorphone, a muopioid analgesic, and acetaminophen, a non-opioid analgesic, on physiological and subjective responses to a stressful public speaking task in healthy human volunteers. In line with our hypothesis, we found that hydromorphone (4 mg) reduced cortisol responses to stress, and it also decreased ratings of how "challenging" they considered the task to be. Interestingly, acetaminophen also reduced ratings of how challenging participants found the task.
The main result of this study is that the mu-agonist hydromorphone reduced cortisol responses to stress and decreased ratings of how "challenging" the task was, one measure of psychological response to stress. In a previous study (Bershad et al., 2015) the partial mu-agonist/ kappa-antagonist buprenorphine also reduced cortisol responses to stress, but it decreased ratings of how "threatening" subjects found the task to be. It is not clear whether the adjectives "challenging" and "threatening" reflect subtly differences in the psychological effects of the two drugs, such as differences in positivity or negativity of the experience. Alternatively, the differences across studies may reflect subtle methodological differences in the testing conditions or subject samples across the two studies. The two drugs, hydromorphone (2 and 4 mg) in the present study and buprenorphine (0.2 and 0.4 mg) in the Bershad et al. study produced similar ratings in "feel high" and "feel drug", suggesting that the doses were comparable.
Both mu and kappa actions are implicated in stress-reducing effects of opioids. In rodents, mu-opioid agonists reduce behavioral manifestations of anxiety in response to stress Kahveci et al., 2006; Stein et al., 2007; Wilson and Junor, 2008) , but there is also growing evidence for a role of kappa receptors. Mice lacking the kappa opioid receptor (KOR) or pretreated with a KOR antagonist fail to develop conditioned place aversion in context associated with repeated physical stressors (Land et al., 2008) , and kappaantagonists block activation of the HPA axis on conditioned place aversion (Land et al., 2008) as well as reducing behavioral responses to social defeat stress in rodents (Funk et al., 2014; McLaughlin et al., 2006) . Indeed these findings have led researchers to consider the therapeutic potential of kappa-antagonists in the treatment of mood disorders (Carlezon and Krystal, 2016) . The fact that the mu agonist hydromorphone dampened cortisol responses to stress, as well as reducing ratings of how challenging the task was, suggests that both mu and kappa mechanisms may contribute to potential therapeutic applications of opioid drugs.
Interestingly, acetaminophen, like hydromorphone, reduced ratings of how challenging participants found the TSST to be, though it did not exert affect other cardiovascular or hormonal dimensions of stress. The apparent reduction in the psychological response to stress is consistent with some reports that acetaminophen reduces responses to negative social input, and has a role in treatment of depression. In mice, COX inhibitors have been shown to reduce anxiety via an endocannabinoid mechanism (Hermanson et al., 2013) , and in humans, these drugs appear to enhance response to standard SSRI treatments for depression (Köhler et al., 2014; Müller et al., 2006) . The mechanism by which acetaminophen reduces affective responses are not known, although there is considerable interest in the idea that inflammation plays an important role in psychiatric symptoms, including depression (DeWall et al., 2015; DeWall et al., 2010; Mischkowski et al., 2016; Randles Fig. 3 . Drug effects on heart rate responses during a) the non-stressful control session (NCST) and b) the TSST session. Shaded area indicates the time during which the TSST took place. Data points represent mean ± SEM. Neither drug significantly affected heart rate. et al., , Müller, 2017 . The role of anti-inflammatory drugs in psychiatric disorders and in non-pathological responses to psychological stress remains to be determined. Because sex differences have been reported in responses to both stress and opioid drugs (Dahan et al., 2008 , Cicero et al., 2000 , Miller and Ernst, 2004 , Lovallo et al., 2012 , 2015 , al'Absi et al., 2008 , we included sex in our analyses. Our findings are consistent with findings by Kelly et al. (2008) that women exhibit greater negative emotional reactivity to simulated stressors than men. However, unlike Kajantie and Phillips (2006) we did not observe significant sex differences in the cortisol response to stress. The effects of the drugs were similar in men and women, which is consistent with our previous findings (Bershad et al., 2016) . The present study was not designed to investigate sex differences, and it is possible that these would be detected with a larger sample, or assessment of women at different phases of the menstrual cycle.
Our study has several limitations. First, the sample size was relatively small, making it difficult to detect small effects of the stress-drug interactions or to assess study individual differences, including those related to sex. Second, conclusions regarding the relative roles of mu and kappa receptors will require direct comparison with receptor-specific agents. Third, we used just one dose of acetaminophen, and only two doses of hydrocodone. It is possible that interactions between these drugs and acute stress might be detected at other doses, or with repeated administration of the drugs (DeWall et al., 2010) . Finally, it is unclear which components of the stress responses are critical for key behavioral or therapeutic outcomes. In our studies, we assess responses to stress in several ways (e.g., momentary levels of stress, assessments of how threatening or challenging the task is, as well as physiological indices of stress). These measures do not always co-vary, and their significance for therapeutic indications remains unknown.
In this study, we compared the effects of a pure mu-opioid agonist on responses to psychosocial stress to those of a non-opioid analgesic. Hydromorphone dampened the hormonal component of the stress response, and both drugs decreased one measure of psychological response, how "challenging" the subjects found the task. These results can be interpreted in light of previous studies with buprenorphine suggesting that both kappa-opioid and mu receptor systems play a role in stress-dampening effects. They also lend modest support to the idea that anti-inflammatory drugs have some value in alleviating psychological stress. Future studies are needed to determine which of the stress-related outcome measures are most relevant to the development of antianxiety and anti-depressant medications.
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